Clinical Outcomes and Risks in Post-Ibrutinib Transplant
In an era marked by rapid advancements in targeted therapies for hematologic malignancies, the management of relapsed or refractory mantle cell lymphoma (MCL) remains a formidable challenge for clinicians. Mantle cell...
Read moreDetails
























